NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/12/2026
Back to search
Official data from USPTO
NANOIMMUNOCEL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NANOIMMUNOCEL
ST13
US500000098931142Class
5, 42
Filing
98931142
Registration
8257279
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
05/12/2026
Trademark type
Word
Nice classes
5, 42
Filing date
12/31/2024
Registration date
05/12/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/12/2026
Last transaction
05/12/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
12/01/2024
First use in commerce
12/01/2024
Drawing code
4
Owner type
03
Owner location
Houston, TX, US
Examiner
MCPHERSON RAYBURN, SHAVELL A
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NANOIMMUNOCEL Inc
Representatives
Justin Johanson Rocket Legal Professional Services, Inc.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Antibodies for medical purposes; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposesfor cancer treatmentoncology and immunotherapy for auto immune diseases; Chemical preparations for pharmaceutical or medical purposesfor cancer immunotherapy; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer
Class 42
Pharmaceutical research and development; Providing information about medical and scientific research via a website; Providing medical and scientific research information; Providing medical research and scientific research information in the field of oncology via the Internet; Consulting services in the field of pharmaceutical research and development; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services in the field of cancer; Providing medical testing services and information in the field of cancer research and disease classification; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/12/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/21/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/21/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/31/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/31/2026
IUAF
USE AMENDMENT FILED
10/01/2025
EISU
TEAS STATEMENT OF USE RECEIVED
10/01/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/16/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/22/2025
PUBO
PUBLISHED FOR OPPOSITION
07/22/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/16/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/14/2025
DOCK
ASSIGNED TO EXAMINER
06/12/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/29/2025
NWAP
NEW APPLICATION ENTERED
12/31/2024
Continuous trademark protection
Get notified about every new filing that threatens NANOIMMUNOCEL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.